Biophytis announces the drawing of the second tranche of ORNANE under the 2021 Atlas Contract for €4 million
Biophytis announces the issuance of the 160 Bonds Redeemable in Cash and New and Existing Shares (ORNANE) for a total amount of €4 million under its existing convertible bond agreement with Atlas, a specialized investment fund based in New York (United States) for €32 million (the “2021 Atlas Contract”).
On June 14, 2021, Biophytis announced a convertible line of €32 million from Atlas. The financing instrument allows the issuance of 1,280 ORNANE, at a par value of €25,000 each. The €32 million total financing are to be drawn by Biophytis over the following 3 years, through 8 successive tranches of €4 million each. This is the second drawing from this instrument.
The Company will keep the shareholders informed of the exercise of the ORNANE issue warrants and the subsequent conversions, through a summary table of issue warrants, the ORNANE, and the number of shares in circulation, which will be available on the Company website.